ADAnita K. Dunbier

Anita K. Dunbier

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anita K. Dunbier has a total of 209 co-authors. Here are the top co-authors by number of shared publications:

  • Mitch Dowsett

    Academic Department of Biochemistry, Royal Marsden Foundation Trust, London, UNITED KINGDOM

    15 shared publications
  • Helen Anderson

    Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London

    10 shared publications
  • Zara Ghazoui

    Authors' Affiliations: 1Academic Biochemistry, Royal Marsden Foundation Trust

    9 shared publications
  • Mitch Dowsett

    The Royal Marsden NHS Foundation Trust, London, United Kingdom

    7 shared publications
  • Parry Guilford

    Department of Biochemistry, University of Otago, Dunedin, New Zealand

    6 shared publications
  • Janine Salter

    Authors' Affiliations: 1Royal Marsden Hospital; 2Breakthrough Breast Cancer Research Centre, Institute of Cancer Research; 3Cancer Research UK Clinical Trials and Statistics Unit, Section of Clinical Trials, Institute of Cancer Research, London; 4Breast Research Group, University of Edinburgh, Edinburgh, United Kingdom; and 5Department of Biochemistry, University of Otago, Dunedin, New Zealand

    5 shared publications

Latest Publications

  • Open Access

    Development of immunocompetent models for primary and metastatic ER + breast cancer

    by Devon M. Bull, Jody Hazlett, Emily Schulpen, Sophie Tunnicliffe, Alexander D. McLellan, Anita K. Dunbier

    Background: The development of effective therapeutic strategies for late‐stage estrogen receptor‐positive breast cancer (ER+) is limited by the scarcity of biologically relevant models. More recently, immunotherapies emerged as promising candidates for breast cancer treatment, however, the absence of immunocompetent models of ER+ breast cancer metastasis continues to hinder the assessment of these theraputic interventions. Methods: To address this, we utilized the 129S6/SvEv mouse strain and syngeneic SSM3 cells in the assessment and development of ER+ metastasis models. As part of this study, the mammary intraductal (MIND) primary tumor model was established in the same background. In addition, a novel luciferase system was evaluated for potential use in metastasis tracking. Results: Luciferase‐expressing SSM3 cells enabled longitudinal in vivo imaging to track tumor growth. Histological analysis confirmed metastatic spread and tumor origin. Antares2, a novel luciferase reporter, showed high in vitro sensitivity but reduced in vivo performance. The study showed that systemic delivery of SSM3 cells with oestradiol supplementation can support metastatic tumor establishment and that MIND injections led to reliable, invasive tumor growth. Conclusions: These findings highlight the potential and limitations of the 129S6/SvEv model as a syngeneic, immunocompetent system for studying ER+ breast cancer metastasis. Reporter expression may affect immunogenicity or cell fitness. Further refinement of these models will enable investigation of immune‐modulatory therapies in ER+ metastatic breast cancer.


  • Open Access

    Restriction site associated DNA sequencing for tumour mutation burden estimation and mutation signature analysis

    by Conor F. McGuinness, Michael A. Black, Anita K. Dunbier

    Background: Genome-wide measures of genetic disruption such as tumour mutation burden (TMB) and mutation signatures are emerging as useful biomarkers to stratify patients for treatment. Clinicians commonly use cancer gene panels for tumour mutation burden estimation, and whole genome sequencing is the gold standard for mutation signature analysis. However, the accuracy and cost associated with these assays limits their utility at scale.Methods: WGS data from 560 breast cancer patients was used for in silico library simulations to evaluate the accuracy of an FDA approved cancer gene panel as well as restriction enzyme associated DNA sequencing (RADseq) libraries for TMB estimation and mutation signature analysis. We also transfected a mouse mammary cell line with APOBEC enzymes and sequenced resulting clones to evaluate the efficacy of RADseq in an experimental setting.Results: RADseq had improved accuracy of TMB estimation and derivation of mutation profiles when compared to the FDA approved cancer panel. Using simulated immune checkpoint blockade (ICB) trials, we show that inaccurate TMB estimation leads to a reduction in power for deriving an optimal TMB cutoff to stratify patients for immune checkpoint blockade treatment. Additionally, prioritisation of APOBEC hypermutated tumours in these trials optimises TMB cutoff determination for breast cancer. The utility of RADseq in an experimental setting was also demonstrated, based on characterisation of an APOBEC mutation signature in an APOBEC3A transfected mouse cell line.Conclusion: In conclusion, our work demonstrates that RADseq has the potential to be used as a cost-effective, accurate solution for TMB estimation and mutation signature analysis by both clinicians and basic researchers.


  • Open Access

    Restriction site associated DNA sequencing for tumour mutation burden estimation and mutation signature analysis

    by Conor F McGuinness, Michael A Black, Anita K Dunbier, Mik Black

    Genome-wide measures of genetic disruption such as tumour mutation burden (TMB) and mutation signatures are emerging as useful biomarkers to stratify patients for treatment. Clinicians commonly use cancer gene panels for tumour mutation burden estimation, and whole genome sequencing is the gold standard for mutation signature analysis. However, the accuracy and cost associated with these assays limits their utility at scale. Using in silico library simulations we demonstrate that restriction enzyme associated DNA sequencing (RADseq) may be a cost-effective solution to improve accuracy of TMB estimation and derivation of mutation profiles when compared to a derived FDA approved cancer gene panel TMB score. Using simulated immune checkpoint blockade (ICB) trials, we show that inaccurate tumour mutation burden estimation leads to a reduction in power for deriving an optimal TMB cutoff to stratify patients for immune checkpoint blockade treatment. Additionally, prioritisation of APOBEC hypermutated tumours in these trials optimises TMB cutoff determination for breast cancer. Finally, the utility of RADseq in an experimental setting is also demonstrated, based on characterisation of an APOBEC mutation signature in an APOBEC3A transfected mouse cell line. In conclusion, our work demonstrates that RADseq has the potential to be used as a cost-effective, accurate solution for TMB estimation and mutation signature analysis by both clinicians and basic researchers.

  • Open Access

    TRIB1 modulates transcriptional programming in breast cancer cells to regulate cell proliferation

    by Hamish D. McMillan, Evangelia K. Papachristou, Jody Hazlett, Soleilmane Omarjee, Jason S. Carroll, Michael A. Black, Peter D. Mace, Anita K. Dunbier

    The pseudokinase Tribbles Homolog 1 ( TRIB1 ) is a known driver of tumorigenesis in acute myeloid leukemia and is encoded upstream of the oncogene MYC at the 8q24 locus. We observed that TRIB1/MYC co-amplification is associated with decreased relapse-free and overall survival in breast cancer patients, but the role of TRIB1 in this disease has not been well characterized. TRIB1 knockdown in multiple breast cancer cell lines inhibited cell proliferation and suppressed MYC expression, implicating TRIB1 in breast cancer cell proliferation. Transcriptomic and cell cycle analysis revealed cell cycle regulation as the likely mechanism through which TRIB1 influences breast cancer cell proliferation. TRIB1 knockdown also resulted in significant changes in both estrogen receptor (ER) and β-catenin associated transcription. Interrogating the TRIB1 interactome in breast cancer cells by qPLEX-RIME reinforced the known association between TRIB1 and ubiquitination, while revealing a range of previously undescribed TRIB1 associated factors. Further analysis of the association between TRIB1, β-catenin and FERMT2 suggests TRIB1 may regulate β-catenin activity by controlling the levels of both β-catenin, and its co-factor FERMT2. Together, these results suggest that coregulation of β-catenin and ER-driven transcription by TRIB1, facilitates regulation of MYC expression and breast cancer cell proliferation. Significance: The pseudokinase TRIB1 is frequently co-amplified in breast cancers with the potent oncogene MYC , although the functional consequences of this event are not well understood. This study demonstrates TRIB1 is a regulator of cell cycle progression and MYC expression in breast cancer cells. It also profiles TRIB1 -associated proteins in breast cancer cells, demonstrating conservation of TRIB1’s canonical interaction with COP1 and reveals associations with members of the wider ubiquitination machinery, a range of transcriptional regulators and chromatin remodelers. The data presented provide insight into the function of TRIB1 in breast cancer and the role of TRIB1 in transcriptional regulation.


  • Open Access

    Structure vs. Function of TRIB1—Myeloid Neoplasms and Beyond

    by Hamish D McMillan, Karen Keeshan, Anita K Dunbier, Peter D Mace

    The Tribbles family of proteins—comprising TRIB1, TRIB2, TRIB3 and more distantly related STK40—play important, but distinct, roles in differentiation, development and oncogenesis. Of the four Tribbles proteins, TRIB1 has been most well characterised structurally and plays roles in diverse cancer types. The most well-understood role of TRIB1 is in acute myeloid leukaemia, where it can regulate C/EBP transcription factors and kinase pathways. Structure–function studies have uncovered conformational switching of TRIB1 from an inactive to an active state when it binds to C/EBPα. This conformational switching is centred on the active site of TRIB1, which appears to be accessible to small-molecule inhibitors in spite of its inability to bind ATP. Beyond myeloid neoplasms, TRIB1 plays diverse roles in signalling pathways with well-established roles in tumour progression. Thus, TRIB1 can affect both development and chemoresistance in leukaemia; glioma; and breast, lung and prostate cancers. The pervasive roles of TRIB1 and other Tribbles proteins across breast, prostate, lung and other cancer types, combined with small-molecule susceptibility shown by mechanistic studies, suggests an exciting potential for Tribbles as direct targets of small molecules or biomarkers to predict treatment response.


  • Open Access

    Variable expression quantitative trait loci analysis of breast cancer risk variants

    by George Wiggins, Michael A Black, Anita Dunbier, Tony R Merriman, John Pearson, Logan C Walker

    Genome wide association studies (GWAS) have identified more than 180 variants associated with breast cancer risk, however the underlying functional mechanisms and biological pathways which confer disease susceptibility remain largely unknown. As gene expression traits are under genetic regulation we hypothesise that differences in gene expression variability may identify causal breast cancer susceptibility genes. We performed variable expression quantitative trait loci (veQTL) analysis using tissue-specific expression data from the Genotype-Tissue Expression (GTEx) Common Fund Project. veQTL analysis identified 70 associations ( p < 5×10 −8 ) consisting of 60 genes and 27 breast cancer risk variants, including 55 veQTL that were observed in breast tissue only. Pathway analysis of genes associated with breast-specific veQTL revealed an enrichment of four genes ( CYP11B1, CYP17A1 HSD3B2 and STAR ) involved in the C21-steroidal biosynthesis pathway that converts cholesterol to breast-related hormones (e.g. oestrogen). Each of these four genes were significantly more variable in individuals homozygous for rs11075995 (A/A) breast cancer risk allele located in the FTO gene, which encodes an RNA demethylase. The A/A allele was also found associated with reduced expression of FTO , suggesting an epi-transcriptomic mechanism may underlie the dysregulation of genes involved in hormonal biosynthesis leading to an increased risk of breast cancer. These findings provide evidence that genetic variants govern high levels of expression variance in breast tissue, thus building a more comprehensive insight into the underlying biology of breast cancer risk loci.

  • Substrate binding allosterically relieves autoinhibition of the pseudokinase TRIB1

    by Sam A. Jamieson, Zheng Ruan, Abigail E. Burgess, Jack R. Curry, Hamish D. McMillan, Jodi L. Brewster, Anita K. Dunbier, Alison D. Axtman, Natarajan Kannan, Peter D. Mace

    Allosteric regulation of the pseudokinase TRIB1 reveals the therapeutic potential of kinase inhibitors.


  • Open Access

    Fatty acid oxidation is associated with proliferation and prognosis in breast and other cancers

    by Aziz Aiderus, Michael A. Black, Anita K. Dunbier

    Altered cellular metabolism is a hallmark of cancer but the association between utilisation of particular metabolic pathways in tumours and patient outcome is poorly understood. We sought to investigate the association between fatty acid metabolism and outcome in breast and other cancers. Cox regression analysis and Gene Set Enrichment Analysis (GSEA) of a gene expression dataset from primary breast tumours with well annotated clinical and survival information was used to identify genesets associated with outcome. A geneset representing fatty acid oxidation (FAO) was then examined in other datasets. A doxycycline-inducible breast cancer cell line model overexpressing the rate-limiting enzyme in FAO, carnitine palmitoyl transferase 1A (CPT1A) was generated and analysed to confirm the association between FAO and cancer-associated characteristics in vitro. We identified a gene expression signature composed of 19 genes associated with fatty acid oxidation (FAO) that was significantly associated with patient outcome. We validated this observation in eight independent breast cancer datasets, and also observed the FAO signature to be prognostic in other cancer types. Furthermore, the FAO signature expression was significantly downregulated in tumours, compared to normal tissues from a variety of anatomic origins. In breast cancer, the expression of CPT1A was higher in oestrogen receptor (ER)-positive, compared to ER-negative tumours and cell lines. Importantly, overexpression of CPT1A significantly decreased the proliferation and wound healing migration rates of MDA-MB231 breast cancer cells, compared to basal expression control. Our findings suggest that FAO is downregulated in multiple tumour types, and activation of this pathway may lower cancer cell proliferation, and is associated with improved outcomes in some cancers.


  • Open Access

    Substrate binding allosterically relieves autoinhibition of the TRIB1 pseudokinase

    by Sam A. Jamieson, Zheng Ruan, Abigail E. Burgess, Jack R. Curry, Hamish D. McMillan, Jodi L. Brewster, Anita K. Dunbier, Alison D. Axtman, Natarajan Kannan, Peter D. Mace

    One Sentence Summary: Substrate binding to Tribbles-homolog 1 (TRIB1) pseudokinase induces allosteric changes that allow formation of a complex with the COP1 ubiquitin ligase. The Tribbles family of pseudokinases recruit substrates to the COP1 ubiquitin ligase for ubiquitination. CCAAT-enhancer binding protein (C/EBP) family transcription factors are crucial Tribbles substrates in adipocyte and myeloid development. Here we show that the TRIB1 pseudokinase can recruit various C/EBP family members, with binding of C/EBPβ attenuated by phosphorylation. To explain the mechanism of substrate recruitment, we solved the crystal structure of TRIB1 in complex with C/EBPα. TRIB1 undergoes a significant conformational change relative to its substrate-free structure, to bind C/EBPα in a pseudo-substrate-like manner. Crucially, substrate binding triggers allosteric changes that link substrate recruitment to COP1 binding, which is consistent with molecular dynamics and biochemical studies. These findings offer a view of pseudokinase regulation with striking parallels to bona fide kinase regulation— via the activation loop and αC-helix—and raise the possibility of small molecules targeting either the activation loop-in, or loop-out, conformations of Tribbles pseudokinases.


  • A PAM50-Based Chemoendocrine Score for Hormone Receptor–Positive Breast Cancer with an Intermediate Risk of Relapse

    by Aleix Prat, Ana Lluch, Arran K. Turnbull, Anita K. Dunbier, Lourdes Calvo, Joan Albanell, Juan de la Haba-Rodríguez, Angels Arcusa, José Ignacio Chacón, Pedro Sánchez-Rovira, et al.

    Purpose: Hormone receptor–positive (HR+) breast cancer is clinically and biologically heterogeneous, and subgroups with different prognostic and treatment sensitivities need to be identified. Experimental Design: Research-based PAM50 subtyping and expression of additional genes was performed on 63 patients with HR+/HER2− disease randomly assigned to neoadjuvant multiagent chemotherapy versus endocrine therapy in a phase II trial. The biology associated with treatment response was used to derive a PAM50-based chemoendocrine score (CES). CES's predictive ability was evaluated in 4 independent neoadjuvant data sets (n = 675) and 4 adjuvant data sets (n = 1,505). The association of CES, intrinsic biology, and PAM50 risk of relapse (ROR) was explored across 6,007 tumors. Results: Most genes associated with endocrine sensitivity were also found associated with chemotherapy resistance. In the chemotherapy test/validation data sets, CES was independently associated with pathologic complete response (pCR), even after adjusting for intrinsic subtype. pCR rates of the CES endocrine–sensitive (CES-E), uncertain (CES-U), and chemotherapy-sensitive (CES-C) groups in both data sets combined were 25%, 11%, and 2%, respectively. In the endocrine test/validation data sets, CES was independently associated with response. Compared with ROR, >90% of ROR-low and ROR-high tumors were identified as CES-E and CES-C, respectively; however, each CES group represented >25% of ROR-intermediate disease. In terms of survival outcome, CES-C was associated with poor relapse-free survival in patients with ROR-intermediate disease treated with either adjuvant endocrine therapy only or no adjuvant systemic therapy, but not in patients treated with (neo)adjuvant chemotherapy. Conclusions: CES is a genomic signature capable of estimating chemoendocrine sensitivity in HR+ breast cancer beyond intrinsic subtype and risk of relapse. Clin Cancer Res; 23(12); 3035–44. ©2016 AACR.